NASDAQ:FGEN - FibroGen Stock Price, Forecast & News

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen Inc (NASDAQ:FGEN) issued its earnings results on Monday, November, 11th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.02. The biopharmaceutical company had revenue of $33.17 million for the quarter, compared to analyst estimates of $31.61 million. FibroGen had a net margin of 11.81% and a return on equity of 7.33%. The business's revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.50) EPS. View FibroGen's Earnings History.

FibroGen is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for FibroGen.

FibroGen will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 equities research analysts have issued 1 year target prices for FibroGen's stock. Their forecasts range from $40.00 to $72.00. On average, they expect FibroGen's share price to reach $52.33 in the next year. This suggests a possible upside of 21.8% from the stock's current price. View Analyst Price Targets for FibroGen.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for FibroGen.

Media coverage about FGEN stock has trended very negative recently, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. FibroGen earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for FibroGen.

FibroGen saw a increase in short interest in January. As of January 31st, there was short interest totalling 5,580,000 shares, an increase of 10.3% from the January 15th total of 5,060,000 shares. Based on an average trading volume of 825,000 shares, the short-interest ratio is presently 6.8 days. Currently, 7.2% of the shares of the company are short sold. View FibroGen's Current Options Chain.

Some companies that are related to FibroGen include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY) and Jazz Pharmaceuticals (JAZZ).

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), ALJ Regional (ALJJ) and Transocean (RIG).

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (10.81%), Janus Henderson Group PLC (3.03%), State Street Corp (3.02%), Farallon Capital Management LLC (1.55%), First Trust Advisors LP (1.50%) and Bank of New York Mellon Corp (1.31%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

FGEN stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., State Street Corp, Handelsbanken Fonder AB, Strs Ohio, Rafferty Asset Management LLC, Citigroup Inc., Bank of America Corp DE and Bank of Montreal Can. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, Elias Kouchakji, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo and Thomas B Neff. View Insider Buying and Selling for FibroGen.

FGEN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Farallon Capital Management LLC, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Credit Suisse AG, Man Group plc, AQR Capital Management LLC and Assenagon Asset Management S.A.. View Insider Buying and Selling for FibroGen.

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FGEN stock can currently be purchased for approximately $42.96.

FibroGen has a market capitalization of $3.75 billion and generates $212.96 million in revenue each year. The biopharmaceutical company earns $-86,420,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. FibroGen employs 461 workers across the globe.View Additional Information About FibroGen.

The official website for FibroGen is http://www.fibrogen.com/.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]